Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results (2022)
Journal Article
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., Shaaban, A. M., …Bliss, J. M. (2022). Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 28(7), 1323 - 1334. https://doi.org/10.1158/1078-0432.CCR-21-3177

PURPOSE: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. PATIENTS AND METHODS: This randomized phase II, two-part, multicenter trial included newly... Read More about Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. (2021)
Journal Article
Meattini, I., Becherini, C., Boersma, L., Kaidar-Person, O., Nader Marta, G., Montero, A., …Coles, C. E. (2022). European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncology, 23(1), e21 - e31. https://doi.org/10.1016/S1470-2045%2821%2900539-8

High-quality randomised clinical trials testing moderately fractionated breast radiotherapy have clearly shown that local control and survival is at least as effective as with 2 Gy daily fractions with similar or reduced normal tissue toxicity. Fewer... Read More about European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer..

Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation (2021)
Journal Article
Brunt, A. M., Haviland, J. S., Kirby, A. M., Somaiah, N., Wheatley, D. A., Bliss, J. M., & Yarnold, J. R. (2021). Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clinical Oncology, 33(7), 430-439. https://doi.org/10.1016/j.clon.2021.04.016

INTRODUCTION: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in rel... Read More about Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.

Moving Forward Fast with FAST-Forward (2021)
Journal Article
Lewis, P., Brunt, A., Coles, C., Griffin, S., Locke, I., & Roques, T. (2021). Moving Forward Fast with FAST-Forward. Clinical Oncology, 33(7), 427-429. https://doi.org/10.1016/j.clon.2021.04.007

International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic (2020)
Journal Article
Coles, C. E., Aristei, C., Bliss, J., Boersma, L., Brunt, A. M., Chatterjee, S., …Rivera, S. (2020). International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology, 32(5), 279-281. https://doi.org/10.1016/j.clon.2020.03.006

'No abstract'